Hypothalamic orexin neurons project to numerous brain areas, including the ventral tegmental 35 area (VTA), which is involved in motivation and food seeking behavior. Here we address how 36 exogenously administered orexin-A, and endogenous orexin 1 receptor (OX1R) activation in the 37 VTA affects feeding behavior. We hypothesized that orexin-A and OX1R antagonist SB334867 38 delivered to the VTA, at doses that were subthreshold for effect when injected into the ventricle, 39 would affect intake of palatable foods in multiple test situations. We first used a hedonic feeding 40 model in which satiated rats selectively consume high-fat diet (HFD). Intra-VTA orexin-A 41 stimulated additional consumption of chow and increased HFD intake in this model. In ad lib-fed 42 rats given daily 30-min test sessions, intra-VTA orexin-A also increased intake of HFD and 0.1M 43 sucrose. Further analysis of licking patterns revealed that that VTA orexin-A increased meal 44 size and licking burst size only toward the end of the meal. Consistent with this finding, a 45 subthreshold dose of VTA orexin-A prevented intake suppression induced by gastrointestinal 46 nutrient infusion. Surprisingly, intra-VTA orexin-A had no effect on operant responding for 47 sucrose pellets on a progressive ratio schedule of reinforcement. A role for endogenous VTA 48 OX1R stimulation is supported by our finding that bilateral VTA injection of the selective OX1R 49 antagonist SB334867 suppressed 0.1M sucrose intake. Together, our data suggest that OX1R 50 activity in the VTA facilitates food intake, potentially by counteracting post-ingestive negative 51 feedback that would normally suppress feeding later in a meal. 
Introduction 60
Mounting evidence supports a critical role for hypothalamic orexin neurons in the control 61 of food intake. Lateral, 3 rd , and 4 th intracerebroventricular (icv) injection of orexin-A increases 62 food intake, as does injection of orexin-A into specific hypothalamic nuclei (14, 19) and the 63 nucleus of the solitary tract (18). Orexin is expressed as a prepro-gene that is post-64 translationally modified to yield two isoforms, orexin-A and orexin-B (29). Orexin-A seems to be 65 the primary isoform involved in feeding control, through its actions at the orexin 1 receptor 66 (OX1R). This is based on observations that selective antagonists for the OX1R decrease food 67 intake, and activation of orexin-2 receptor by orexin-B typically does not affect feeding (10, 13) . 68
The decrease in food intake after peripheral OX1R antagonist treatment seems to occur 69 independent of changes in malaise (17). OX1R activity in some brain regions strongly influences 70 spontaneous physical activity and arousal, which could in turn affect feeding. However, 71 hindbrain application of orexin-A and the OX1R antagonist SB334867 affect feeding without 72 altering physical activity (24) , suggesting that at least in some locations, OX1R have a 73 physiologic role in the control of feeding. 74
Orexin neurons appear to play a role in both food and drug reward. Studies using 75 conditioned place preference (CPP) as a model of drug reinforcement report that mice lacking 76 the prepro-orexin gene fail to express a CPP for a morphine-paired environment (23). In other 77 studies, exposure to the CPP compartment previously paired with morphine, cocaine, or food 78 leads to increased activation of orexin neurons in the lateral hypothalamus (LH) and expression 79 of morphine-CPP can be attenuated by blockade with orexin-A antagonist before the post-80 training preference test session (11). These observations indicate that LH orexin neurons are 81 activated by environmental cues that signal availability of reinforcing stimuli. Consistent with 82 dose was subthreshold for effect when delivered to the 4 th ventricle. All experiments utilized a 164 within-subjects counterbalanced design, and experimental days were separated by 48 h. All 165 experiments were conducted during the mid-light phase. 166
Experiment 1: Effect of Unilateral VTA Orexin-A on Feeding in a Dessert Model 167
Unilateral VTA-cannulated rats (n = 8) were food-deprived for 48 h, and were 168 subsequently given ad libitum access to chow. Ninety min after the initiation of chow access, 169 rats received intra-VTA injection of saline vehicle or 0.5 nmol orexin-A. Chow remained 170 available and high fat diet (HFD; 60% fat, Research Diets) was introduced 30 min post-injection. 171
Intake of chow was measured at 1, 2, and 3 hours. HFD was measured from hour 2 to hour 3. 172
Rats recovered for 6 days before the second food deprivation period began. Drug treatments 173
were presented in counterbalanced order. 174
Experiment 2: Effect of Unilateral VTA Orexin-A on High-Fat Diet (HFD) Intake 175
Naive rats (n = 10) with VTA cannulas were habituated to receive 30-min access to a 176 pre-weighed hopper filled with HFD in their home cages 5 or 6 days per week during the mid-177 light phase, always at the same time of day. Chow was removed from the cage during these test 178 sessions. After the 30-min test period, HFD was removed from the cage and weighed, and chow 179 was returned. The experiment began after rats were habituated to this test situation for 8 days, 180 at which point HFD intakes were stable (less than 10% variation over 3 consecutive days). On 181 experimental days, rats received intra-VTA injections of either 0.1 nmol or 0.5 nmol of orexin-A 182 or saline vehicle 30 min before the HFD intake test. 183 Experiment 3: Effects of Unilateral VTA Orexin-A or OX1R antagonist on Sucrose Intake 184 VTA-cannulated rats (n = 15) were given 30 min access to 0.1M sucrose in a pre-185 weighed bottle placed on their home cage, with no access to chow or water during the session 5 186 or 6 days per week. After 16 days, sucrose intake was stable across days and the experiment 187 began. On experiment days, food and water were removed prior to injections. Rats received 188 intra-VTA injections of either 0.1 nmol or 0. Kay et al. (18) . Two levers were present in each chamber; presses on the active 203 lever were reinforced, whereas inactive lever presses were not reinforced (rats rarely pressed 204 the inactive lever). For all training and testing sessions, there was a, 5-s timeout after each 205 reinforcement. During both training and test sessions, a cue light was illuminated above the 206 active lever. The locations of the active and inactive levers were counterbalanced across 207 subjects. Training progressed as follows: first, rats were trained on a fixed ratio one schedule 208 (FR1) where each response resulted in delivery of one sucrose pellet. FR1 training was 209 conducted for 9 days. Next, rats were moved to a FR3 schedule where three responses were 210 required to achieve one sucrose pellet for 7 days. Following this training, all rats showed less 211 than 10% day-to-day variation in responding and were switched to a progressive ratio (PR) 212 schedule that followed the algorithm of Richardson and Roberts (27): 1, 2, 4, 6, 9, 12, 16, 20, 213 28, 36, 48, etc … lever presses for reinforcement. PR sessions ended when the rat failed to 214 press the active lever for 30 minutes, with a maximum duration of 2 h. Rats were then returned 215 to home cages with ad libitum food and water access. Experimentation began after 8 days of 216 PR training, at which point rats showed stable responding on the PR schedule. On testing days, 217 rats received intra-VTA injection of saline vehicle, 0.1 nmol, or 0.5 nmol orexin-A 30 minutes 218 before the start of the PR session. Rats (n = 8) were trained to consume 0.1M sucrose in daily home cage test sessions as 246 described in experiment 3, but these rats were also first connected to infusion lines in the 247 operant chambers described in experiment 5. No manipulanda, spouts, or food were available 248 during this time; these chambers were simply used for infusions. The infusion lines consisted of 249 polyethylene tubing (PE; VWR, Radnor, PA) protected by a stainless steel spring. The PE 250 tubing was connected to an infusion swivel (Instech Solomon, Plymouth Meeting, PA) mounted 251 on a counterbalanced lever at the top of the chamber. This conserved the rats' ability to move 252 freely around the chamber when the infusion line was connected to the back-mounted IG 253 catheter port. When daily 0.1M sucrose intakes were stable, rats received an additional 254 habituation test session in which they entered the chamber to receive an IG infusion of 0.9% 255 saline at a rate of 1 ml/min for 5 min, and were then returned to their home cage and given 256 access to the pre-weighed sucrose bottle for 30 min. 257
This experiment had 4 conditions that were administered to all rats in a counterbalanced 258 order separated by minimum of 48 h. Rats received an intra-VTA injection of either saline 259 vehicle or 0.025 nmol orexin-A 40 min before the start of the intake test. This dose was chosen 260 based on a pilot study in which we observed no effect of intra-NTS 0.025 nmol of orexin-A. 261
Thirty min after the intra-VTA injections, rats were connected to the infusion lines. They then 262 received 5 ml of either 0.9% saline or 25% sucrose (5 kcal) delivered at a rate of 1 ml/min for a 263 total of 5 min. We chose this sucrose load and timing to induce post-ingestive negative 264 feedback that would significantly suppress subsequent voluntary intake for a short period of 265 time. After the intragastric infusion, rats were disconnected from the infusion line, returned totheir home cages, and given access to 0.1M sucrose for 30 min. The 4 experimental conditions 267 were: VTA vehicle/IG saline; VTA vehicle/IG sucrose; VTA orexin-A/IG saline; VTA orexin-A/IG 268 sucrose. 269
Statistical analysis 270
Data are reported as mean ± SEM. Effects were evaluated by within-subjects Student's t 271 test or within-subjects one-way ANOVA, as appropriate. Drug effects on licking variables across 272 segments of the meal in experiment 6 were assessed by two-factor ANOVA with drug and 273 segment as factors. Similarly, in experiment 7, a two-factor ANOVA was used to assess the 274 effect of IG sucrose and VTA orexin-A on sucrose intake. Pairwise planned comparisons were 275 made with Holm-Sidak tests. P-values of < 0.05 were taken as significant. 276
Results

277
Experiment 1: Effect of Unilateral VTA Orexin-A on Feeding in a Dessert Model 278
Following 48 h food deprivation, there was no difference in 1 h chow intake between 279 groups prior to injections. Intra-VTA orexin-A significantly increased chow intake at the 2 h 280 measurement, which occurred 30 min post injection (t (7) =3.17, p<0.01) ( Fig. 2A) . When rats 281 were exposed to HFD after re-feeding on chow, intra-VTA orexin-A significantly elevated HFD 282 intake from hour 2 to 3 (t (7) =2.13, p<0.05) (Fig. 2B) . There was no effect on chow intake from 283 hour 2 to 3 ( Fig. 2A) . p<0.05). Here, only the 0.5 nmol dose significantly increased HFD intake (p<0.05) relative to 287 vehicle (Fig. 3) . 288
Experiment 3: Effects of Unilateral VTA OX1R Stimulation or Blockade on Sucrose Intake 289
Intra-VTA orexin-A strongly and significantly increased 30 min home cage sucrose 290 intake (F (2, 28) =15.29, p<0.0001). Both the 0.1 and 0.5 nmol dose significantly elevatedsucrose intake relative to intra-VTA vehicle injection (Fig. 4) . The same rats failed to suppress 292 30 min sucrose intake after unilateral VTA injection of SB334867, tested 5 days after the orexin-293 A experiment ended. There was a nonsignificant trend toward an increase in 30 min sucrose 294 intake after SB334867 from a mean of 14.42 ± 1.48 grams after vehicle and 16.85 ± 1.86 grams 295 after SB334867. 296
Experiment 4: Effect of Bilateral VTA OX1R Blockade on Sucrose Intake 297
Bilateral intra-VTA injection of SB334867 significantly suppressed 30-min sucrose intake 298 (t (8) =2.01, p<0.05) (Fig 5) . 299
Experiment 5: Effect of Unilateral VTA OX1R Stimulation on Operant Responding 300
Unilateral VTA orexin-A injection had no effect on breakpoint (the last completed ratio of 301 the session), active lever presses, or number of reinforcers earned in rats responding under a 302 PR schedule for sucrose (Fig. 6) . VTA orexin-A had a tendency to increase the duration of the 
Sucrose 308
Unilateral VTA orexin-A significantly increased first meal size (t (8) =2.88, p<0.05) (Fig.  309 7A) but had no effect on number of bursts taken within that meal or meal duration (Table 1) . The 310 number of licks in the first minute of the first meal tended to be suppressed after intra-VTA 311 orexin-A, but this did not reach significance (Table 1) . When the first meal was segmented into 312 thirds by total number of licking bursts within the meal, effects of orexin-A emerged near the end 313 of the meal, with no effects on licking behavior toward the beginning of the meal. There was a 314 significant main effect of orexin-A on number of licks/meal segment (F(1,8) = 8.266, p < 0.05), 315
and pairwise comparisons show that licks/segment were only significantly elevated by VTA 316 orexin-A in the third segment of the meal (p < 0.05). There was a significant interaction betweenorexin-A and meal segment for burst size (F(2,16) = 4.667, p < 0.05), where orexin-A increased 318 burst size only during the final third of the meal (p<0.05) (Fig. 7) . 319 Experiment 7: Effect of Unilateral VTA Orexin-A on the response to intragastric nutrient 320 infusion 321 IG sucrose infusion significantly suppressed 30 min sucrose intake (F(1,7) = 30.96, p< 322 0.01) (Fig. 8) . As expected, 0.025 nmol orexin-A injected into the VTA had no effect when 323 followed by saline IG infusion. However, this dose of orexin-A significantly attenuated the 324 suppressive effect of the IG sucrose infusion on 30 min sucrose intake (interaction between IG 325 infusion and orexin-A (F(1,7) = 8.56, p <0.05) (Fig. 8) . 326
Discussion 327
The goal of the present experiments was to evaluate the hypothesis that orexin-A acts in 328 the VTA to promote palatable food intake. To do this we manipulated VTA orexin signaling 329 under multiple different feeding conditions. Overall, the results support our hypothesis. 330 Importantly, we found that VTA administration of orexin-A, at doses that were ineffective when 331 delivered to the cerebral ventricles (2, 5), increased intake of palatable, energy dense HFD both 332 in rats that had just consumed a large chow meal and in rats given acute daily access to HFD 333 without a chow pre-load. In addition, VTA orexin-A increased intake of 0.1M sucrose solution in 334 short test sessions. While unilateral blockade of VTA OX1R was not sufficient to affect sucrose 335 intake, bilateral blockade of VTA OX1R with OX1R antagonist SB334867 significantly 336 suppressed sucrose intake during a 30-min test. This finding suggests that endogenous OX1R 337 stimulation in the VTA plays a role in promoting intake of sucrose under these test conditions. 338
Together these data suggest that both exogenous and endogenous VTA OX1R stimulation 339 promotes palatable food intake. 340
To further examine the behavioral mechanisms through which VTA orexin-A influences 341 intake of palatable foods, we determined the effect of VTA orexin-A on licking behavior for 0.1M 342 sucrose solution. Rats were trained to lick a spout for 0.1M sucrose during daily 45-minsessions. Under these conditions, rats took only one meal during the session, and that meal 344 was significantly larger after VTA orexin-A treatment. When the meal was segmented into thirds, 345 to allow examination of potential effects early vs. late in the meal, we found that VTA orexin-A 346 increased licking and burst size near the end of the meal, with no effects near the start of the 347 meal. The effect of VTA orexin-A on the pattern of licking for sucrose suggests that the drug's 348 effect may depend on the accumulation of nutrients in the gut as the meal progresses. reduces HFD intake following a chow pre-load (5, 6). In the present study, VTA orexin-A-treated 360 rats significantly increased chow intake during re-feeding and HFD intake once chow intake had 361 ceased. Furthermore, previous studies report increased neuronal activity within VTA neurons in 362 rats that are expecting palatable chocolate meal (5). This observation suggests that VTA activity 363 might contribute to intake of palatable food. The data we present here are in agreement with 364 these previous findings and extend them by providing novel evidence that orexin action in the 365 VTA stimulates HFD intake in the presence or absence of a caloric pre-load. In addition, the 366 finding that orexin-A in the VTA influences both re-feeding from chow and HFD following a 367 caloric pre-load, along with the observed effects on licking behavior during a meal, suggest that 368 VTA orexin may interact with post-ingestive processes that would typically inhibit feeding after alarge meal. We directly tested this hypothesis in experiment 7, and found that an otherwise 370 subthreshold dose of orexin-A could prevent gastrointestinal nutrient infusion-induced intake 371 suppression. These data strongly support the idea that VTA orexin-A attenuates post-ingestive 372 negative feedback following a nutrient load. 373 Surprisingly, we found that the same dose of VTA orexin-A that robustly increased 0.1M 374 sucrose intake did not affect operant responding for sucrose pellets on a PR schedule. This 375 suggests that activation of OX1R in the VTA does not increase motivation to obtain sucrose 376 pellets, at least under the conditions of this PR experiment. This was contrary to our original 377 hypothesis, because the VTA has a well-established role in motivation, and orexin neurons have 378 been implicated in food reward (1). Previously we have shown that activation of hindbrain OX1R 379 increases motivation for sucrose reinforcement, demonstrated by an increased breakpoint on a 380 PR schedule, while blockade of hindbrain OX1R significantly decreased PR responding and 381 breakpoint (18). These findings suggested that hindbrain orexin increases motivation for 382 sucrose pellets, but our current results do not support a role for VTA orexin to affect operant 383 responding for food reinforcement. This does not rule out the possibility that VTA OX1R play a 384 role in other aspects of food reward that were not assessed here (e.g., conditioned place 385 preference, cue-induced feeding). 386
Under the conditions of the PR experiment, rats consumed few kcal and therefore would 387 have experienced relatively little post-ingestive negative feedback. Given our findings that VTA 388 orexin-A affected food intake primarily late in the meal, and perhaps by interacting with post-389 ingestive feedback signals, it is possible that the lack of effect on PR responding is related to 390 the lack of significant post-ingestive negative feedback in this test situation. Previous work 391 demonstrated that 3 rd ventricular orexin-A infusion significantly increased operant responding on 392 a PR schedule of reinforcement under very similar experimental conditions, so substantial post-393 ingestive negative feedback is clearly not required for orexin-A to influence motivation 394 presumably through actions on its receptors in other brain regions (5). It is also notable that inour sucrose solution intake experiments (experiments 3, 6, 7) where we do find a robust effect 396 of VTA orexin, rats also consumed very few kcal during those test sessions. A key difference 397 between the intake and PR experiments is that the small number of 45-mg pellets consumed in 398 the PR study would not be expected to produce significant gastric distention, whereas the 0.1M 399 sucrose intake was of sufficient volume that a distention signal should have been generated. 400
This difference highlights gastric distention as a specific type of post-ingestive negative 401 feedback signal with which orexin-A in the VTA may interact, and this will be an important 402 subject for future investigation. 403
Previous work has established that orexin-A plays a role in spontaneous physical activity 404 (19). However, orexin-A effects on feeding have been demonstrated without concurrent effects 405 on activity in some cases, so these effects can occur independent of each other (24). We did 406 not examine the effect of VTA orexin-A on physical activity or arousal here, and it is known that 407 the VTA can influence physical activity (34), so it is possible that some of the effects we 408 observed on feeding are related to general arousal or activity. Some observations from the 409 present studies suggest that this may not have been a substantial factor. In the operant 410 responding experiment, VTA orexin-A had no effect on active lever presses or inactive lever 411 presses. If VTA orexin-A increased general arousal or physical activity, we might expect to see 412 increased lever pressing, particularly increased pressing on the inactive lever, but instead there 413 were no effects of orexin-A on active or inactive lever pressing. Although beyond the scope of 414 the present studies, it will be worthwhile to directly investigate whether VTA OX1R influence 415 physical activity in the future. 416 417
Perspectives and Significance 418
The present results indicate that VTA orexin-A influences feeding, particularly intake of 419 palatable foods. While the VTA is best known for its role in reward and motivated behaviors, our 420 findings suggest that VTA orexin receptor stimulation promotes intake not by increasing 421 motivation for food, but potentially through attenuating or opposing post-ingestive negative 422 feedback processes that begin to occur after a meal has been initiated. The idea that the VTA 423 responds to post-ingestive negative feedback signals is relatively new but supported by other 424 recent work. For example, Mietlicki-Baase and colleagues (22) demonstrated that receptors for 425 the satiation signal amylin in the VTA play a physiologic role in the control of feeding. In 426 addition, the adiposity signal leptin acts in the VTA to control palatable food intake (16) and 427 operant responding for sucrose (11). The VTA has also been identified as a site where amylin 428 and leptin interact to reduce food intake (21). The orexin neuron-to-VTA pathway has already 429 been implicated in the effects of other manipulations that affect food intake. For example, OX1R 430 activity in the VTA plays a mediatory role in the feeding responses to icv ghrelin (7) and intra-431 NAc DAMGO (35). OX1R activity also appears to mediate the VTA DA neuronal response to 432 reduced glucose levels (30). Thus, the VTA seems to be a site of integration for diverse signals 433 that influence food intake, perhaps more so that previously appreciated. Future studies will be 434 necessary to determine the mechanisms through which OX1R activity in the VTA influences 435 palatable food intake, and how these receptors interact with other signals at this location. timeline B. After a 48 h food deprivation, rats showed no difference in 1 h chow intake. Intra-561 VTA orexin-A significantly increased chow intake at 2 h (30 min post injection). *p<0.05. There 562 was no effect on chow intake from hour 2 to 3. C. Rats were given access to HFD from hour 2 to 563 3. During this time, intra-VTA orexin-A significantly elevated HFD intake. *p<0.05. Data are means (±SE). In study 6, rats licking for 0.1M sucrose were treated intra-VTA with vehicle or 0.5 nmol orexin-A. *p<0.05; #p = 0.088. Table 1 . Licking microstructural variables measured in study 6
